The effect of exacerbation history on outcomes in the IMPACT trial

IMPACT, a 52-week, randomised, double-blind trial, assessed the efficacy and safety of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy FF/VI or UMEC/VI in patients with symptomatic COPD and a history of exacerbations.Subgroup analyses assessed whether the efficacy of FF/UMEC/...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The European respiratory journal 2020-05, Vol.55 (5), p.1901921
Hauptverfasser:	Halpin, David M G, Dransfield, Mark T, Han, MeiLan K, Jones, C Elaine, Kilbride, Sally, Lange, Peter, Lipson, David A, Lomas, David A, Martinez, Fernando J, Pascoe, Steve, Singh, Dave, Wise, Robert, Criner, Gerard J
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Inhalation Adrenergic beta-2 Receptor Agonists - administration & dosage Adrenergic beta-2 Receptor Agonists - adverse effects Aged Androstadienes - administration & dosage Androstadienes - adverse effects Benzyl Alcohols - administration & dosage Benzyl Alcohols - adverse effects Bronchodilator Agents - administration & dosage Bronchodilator Agents - adverse effects Chlorobenzenes - administration & dosage Chlorobenzenes - adverse effects Disease Progression Double-Blind Method Drug Combinations Female Health Status Humans Lung - drug effects Lung - physiopathology Male Middle Aged Muscarinic Antagonists - administration & dosage Muscarinic Antagonists - adverse effects Nebulizers and Vaporizers Original Pulmonary Disease, Chronic Obstructive - diagnosis Pulmonary Disease, Chronic Obstructive - drug therapy Pulmonary Disease, Chronic Obstructive - physiopathology Quinuclidines - administration & dosage Quinuclidines - adverse effects Recovery of Function Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!